VYSIS INC
10-Q, EX-27, 2000-11-13
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: VYSIS INC, 10-Q, 2000-11-13
Next: MERIDIAN GOLD INC, 6-K, 2000-11-13



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          10,675
<SECURITIES>                                         0
<RECEIVABLES>                                    4,573
<ALLOWANCES>                                   (1,044)
<INVENTORY>                                      1,891
<CURRENT-ASSETS>                                16,817
<PP&E>                                          12,148
<DEPRECIATION>                                 (9,723)
<TOTAL-ASSETS>                                  20,652
<CURRENT-LIABILITIES>                            7,384
<BONDS>                                              0
                                0
                                          0
<COMMON>                                            10
<OTHER-SE>                                      12,144
<TOTAL-LIABILITY-AND-EQUITY>                    20,652
<SALES>                                         15,583
<TOTAL-REVENUES>                                17,442
<CGS>                                            3,958
<TOTAL-COSTS>                                   19,840
<OTHER-EXPENSES>                                   541
<LOSS-PROVISION>                                  (60)
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (1,364)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (1,364)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,364)
<EPS-BASIC>                                     (0.14)
<EPS-DILUTED>                                   (0.14)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission